LI
CCXI

Leap Investments’s ChemoCentryx, Inc. CCXI Stock Holding History

Leap Investments’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,600
Closed -$160K – 645
2019
Q3 		$160K Buy
+23,600
New +$177K 0.08% 328

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Leap Investments's CCXI Position: Q4 2019 in Review

Leap Investments sold out of ChemoCentryx, Inc. (CCXI) in Q4 2019, closing a stake of 23,600 shares — an estimated $160K sold.

Leap Investments first reported a position in CCXI in Q3 2019 and held it in 1 quarter. The position peaked at $160K in Q3 2019. 126 funds tracked by Wall St. Rank hold CCXI as of Q4 2019.

  • Leap Investments reported no remaining ChemoCentryx, Inc. position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 23,600 ChemoCentryx, Inc. shares in Q4 2019, an estimated $160K.
  • Leap Investments first reported a position in ChemoCentryx, Inc. in Q3 2019 and held it in 1 quarter.
  • Leap Investments's ChemoCentryx, Inc. position peaked at $160K in Q3 2019.
  • 126 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.